A review of plant-based expression systems as a platform for single-domain recombinant antibody production

Malaquias, Ângela Donato Maia; Marques, Lívia Érika Carlos; Pereira, Soraya dos Santos; Fernandes, C. de F.; Maranhão, Andréa Queiroz; Stábeli, Rodrigo G.; Florean, Eridan Orlando Pereira Tramontina; Guedes, Maria Izabel Florindo; Fernandes, Carla Freire Celedônio

doi:10.1016/j.ijbiomac.2021.10.126

Cited by 15 publications

(14 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… Ztaou et al (2016) found that bilateral activation of indirect pathway MSNs by optogenetics can produce Parkinson’s-like presentation. However, activation of MSNs in the direct pathway alleviates symptoms such as freezing, bradykinesia, and difficulty in initiating movement ( Kravitz et al, 2010 ; de Almeida and da Silva, 2021 ; Malaquias et al, 2021 ; Yang X. et al, 2021 ). Yang et al (2018) found that the use of optogenetics combined with deep brain stimulation (DBS) ( Castano-Candamil et al, 2019 ) to stimulate the afferent axons of the subthalamic nucleus region at high frequency can significantly treat Parkinson’s disease ( Table 1 and Figure 3 ).…”

Section: Nervous System-based Clinical Researchmentioning

confidence: 99%

The Roles of Optogenetics and Technology in Neurobiology: A Review

Chen

Liang

et al. 2022

Front. Aging Neurosci.

View full text Add to dashboard Cite

Optogenetic is a technique that combines optics and genetics to control specific neurons. This technique usually uses adenoviruses that encode photosensitive protein. The adenovirus may concentrate in a specific neural region. By shining light on the target nerve region, the photosensitive protein encoded by the adenovirus is controlled. Photosensitive proteins controlled by light can selectively allow ions inside and outside the cell membrane to pass through, resulting in inhibition or activation effects. Due to the high precision and minimally invasive, optogenetics has achieved good results in many fields, especially in the field of neuron functions and neural circuits. Significant advances have also been made in the study of many clinical diseases. This review focuses on the research of optogenetics in the field of neurobiology. These include how to use optogenetics to control nerve cells, study neural circuits, and treat diseases by changing the state of neurons. We hoped that this review will give a comprehensive understanding of the progress of optogenetics in the field of neurobiology.

show abstract

Section: Nervous System-based Clinical Researchmentioning

confidence: 99%

The Roles of Optogenetics and Technology in Neurobiology: A Review

Chen

Liang

et al. 2022

Front. Aging Neurosci.

View full text Add to dashboard Cite

show abstract

“…Plants have long been considered advantageous platforms for large-scale production of antibodies, because they constitute an inexpensive, efficient, and safe alternative system ( Giritch et al, 2006 ; Juarez et al, 2016 ; Edgue et al, 2017 ). In addition to full-size mAbs, smaller antibody fragments capable of antigen binding are also actively studied and employed in medicine and research ( Yusibov et al, 2016 ; Julve Parreño et al, 2018 ; Satheeshkumar, 2020 ; Malaquias et al, 2021 ; Wang et al, 2021 ). An interesting new alternative to mAbs are nanobodies ( Muyldermans, 2013 ).…”

Section: Introductionmentioning

confidence: 99%

Production of Potyvirus-Derived Nanoparticles Decorated with a Nanobody in Biofactory Plants

Martí

Merwaiss

Butković

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Viral nanoparticles (VNPs) have recently attracted attention for their use as building blocks for novel materials to support a range of functions of potential interest in nanotechnology and medicine. Viral capsids are ideal for presenting small epitopes by inserting them at an appropriate site on the selected coat protein (CP). VNPs presenting antibodies on their surfaces are considered highly promising tools for therapeutic and diagnostic purposes. Due to their size, nanobodies are an interesting alternative to classic antibodies for surface presentation. Nanobodies are the variable domains of heavy-chain (VHH) antibodies from animals belonging to the family Camelidae, which have several properties that make them attractive therapeutic molecules, such as their small size, simple structure, and high affinity and specificity. In this work, we have produced genetically encoded VNPs derived from two different potyviruses—the largest group of RNA viruses that infect plants—decorated with nanobodies. We have created a VNP derived from zucchini yellow mosaic virus (ZYMV) decorated with a nanobody against the green fluorescent protein (GFP) in zucchini (Cucurbita pepo) plants. As reported for other viruses, the expression of ZYMV-derived VNPs decorated with this nanobody was only made possible by including a picornavirus 2A splicing peptide between the fused proteins, which resulted in a mixed population of unmodified and decorated CPs. We have also produced tobacco etch virus (TEV)-derived VNPs in Nicotiana benthamiana plants decorated with the same nanobody against GFP. Strikingly, in this case, VNPs could be assembled by direct fusion of the nanobody to the viral CP with no 2A splicing involved, likely resulting in fully decorated VNPs. For both expression systems, correct assembly and purification of the recombinant VNPs was confirmed by transmission electron microscope; the functionality of the CP-fused nanobody was assessed by western blot and binding assays. In sum, here we report the production of genetically encoded plant-derived VNPs decorated with a nanobody. This system may be an attractive alternative for the sustainable production in plants of nanobody-containing nanomaterials for diagnostic and therapeutic purposes.

show abstract

“…Furthermore, protein drugs contributed to approximately 10% of the drug market in 2017 ( Usmani et al., 2017 ). For biopharmaceuticals specifically, plants have already been shown to be a viable expression platform, and have been recently reviewed ( Shanmugaraj et al., 2020 ), especially for the production of antibodies ( Malaquias et al., 2021 ). Traditionally, mammalian cell cultures are the most favourable expression chassis, and between 2014 and 2018 they were used to produce 84% of novel recombinant proteins, while E. coli cell cultures were used for production of 8% and S. cerevisiae for 6.5% ( Walsh, 2018 ).…”

Section: Introductionmentioning

confidence: 99%

“…There is however an emerging potential for plants to be used as RP expression systems. Plant-made antibodies, or plantibodies, have been investigated as early as 1989 ( Hiatt et al., 1989 ), and have had dramatic success in recent years ( Malaquias et al., 2021 ), for example in producing a successful vaccine for the Ebola outbreak ( Zhang et al., 2014 ), demonstrating that the system is suitable for expression of complex proteins with high yields. Moreover, technologies are developing that allow dramatically improved protein yields in plants, such as hyper-translatable viral elements for transgenes ( Thuenemann et al., 2013 ) and commercially viable plant expression tools ( Sainsbury et al., 2009 ).…”

Section: Introductionmentioning

confidence: 99%

Optimising expression and extraction of recombinant proteins in plants

Coates

Young²,

Scofield³

2022

Front. Plant Sci.

View full text Add to dashboard Cite

Recombinant proteins are of paramount importance for research, industrial and medical use. Numerous expression chassis are available for recombinant protein production, and while bacterial and mammalian cell cultures are the most widely used, recent developments have positioned transgenic plant chassis as viable and often preferential options. Plant chassis are easily maintained at low cost, are hugely scalable, and capable of producing large quantities of protein bearing complex post-translational modification. Several protein targets, including antibodies and vaccines against human disease, have been successfully produced in plants, highlighting the significant potential of plant chassis. The aim of this review is to act as a guide to producing recombinant protein in plants, discussing recent progress in the field and summarising the factors that must be considered when utilising plants as recombinant protein expression systems, with a focus on optimising recombinant protein expression at the genetic level, and the subsequent extraction and purification of target proteins, which can lead to substantial improvements in protein stability, yield and purity.

show abstract

A review of plant-based expression systems as a platform for single-domain recombinant antibody production

Cited by 15 publications

References 65 publications

The Roles of Optogenetics and Technology in Neurobiology: A Review

The Roles of Optogenetics and Technology in Neurobiology: A Review

Production of Potyvirus-Derived Nanoparticles Decorated with a Nanobody in Biofactory Plants

Optimising expression and extraction of recombinant proteins in plants

Contact Info

Product

Resources

About